| ACE | Angiotensin-converting enzyme |
| AE | Adverse event |
| ARB | Angiotensin receptor blocker |
| aROR | Adjusted reporting odds ratio |
| BB | Beta-adrenergic receptor blocker |
| CI | Confidence interval |
| cROR | Crude reporting odds ratio |
| CV | Cardiovascular |
| CYP | Cytochrome P450 enzyme |
| DHP-CCB | Dihydropyridine calcium channel blocker |
| DOAC | Direct oral anticoagulant |
| EBGM | Empirical Bayesian geometric mean |
| FAERS | Food and Drug Administration Adverse Event Reporting System |
| GERD | Gastroesophageal reflux disease |
| GI | Gastrointestinal |
| H2RA | Histamine 2 receptor antagonist |
| IC | Information component |
| ICSR | Individual case safety report |
| LCI | Lower limit of 95% confidence interval |
| LLT | Lowest-level term |
| NDHP-CCB | Non-dihydropyridine calcium channel blocker |
| NSAID | Non-steroidal anti-inflammatory drug |
| OAC | Oral anticoagulant |
| PCAB | Potassium-competitive acid blocker |
| P-gp | P-glycoprotein |
| PPI | Proton pump inhibitor |
| PRR | Proportional reporting ratio |
| ROR | Reporting odds ratio |